As an early investor in Dyne Therapeutics, CureDuchenne is pleased share that Dyne announced positive data from their Phase 1/2 trial of DYNE-251 in individuals with Duchenne amenable to skipping […]
Letter to the Duchenne Community – INSPIRE DUCHENNE update Dear Duchenne Community, We are writing to share an important update on INSPIRE DUCHENNE, our Phase 1/2 clinical trial of SGT-003 for […]
Avidity Biosciences, which received early funding from CureDuchenne, announced positive initial data from their EXPLORE44 Trial for individuals with Duchenne amenable to skipping exon 44. Their experimental exon-skipping agent, AOC […]
Link to press release We are thrilled to share the latest data from RegenXBio’s microdystrophin gene therapy, AFFINITY DUCHENNE®. RGX-202 is a one-time gene therapy for Duchenne designed to deliver […]
Pfizer Duchenne Program Discontinuation: Pfizer has officially decided to discontinue their microdystrophin gene therapy program for Duchenne, after the sad announcement last month that the Phase 3 trial failed to […]
First nonsteroidal treatment approved for patients six years of age and older with DMD regardless of genetic mutation now available in the U.S. ITF also announces the launch of ITF […]
READ THE FULL PRESS RELEASE HERE Introduction The journey towards finding effective treatments for Duchenne Muscular Dystrophy (DMD) has been marked by significant milestones. However, recent findings indicate that we […]
There is no excerpt because this is a protected post.
Dyne Therapeutics shares with the community recent efficacy and safety data from the ongoing DELIVER trial of DYNE-251 in Duchenne. Watch HERE
